The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for centanafadine, an investigational, once-daily extended-release capsule for attention-deficit hyperactivity disorder (ADHD) treatment.
We believe our product DEXTENZA for AC has potential as a hands-free therapy administered in the office setting as a bioresorbable, intracanalicular insert, designed to release the corticosteroid
Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response
The company’s AAVSmartLibrary and associated technology are said to be used for developing AAV capsids for enhanced tissue tropism, manufacturability, and pre-existing immunity. The collaboration will make use
The breakthrough therapy status will allow using of mobocertinib by patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has advanced on or after
The data will be presented as a virtual poster at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. This ongoing study is an open
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
